CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial

Positive
AI Analysis

Summary

Yarrow Bioscience priced a $150 million offering at $26 per share. AbbVie's drug succeeded in a menstrual migraine trial.

Importance:6/10
Sentiment:
0.60
capital_raiseofferingphase_3_successmenstrual_migraine
Related Companies

Read the original article

Published by Endpoints News on September 11, 2026 3:28 PM

Read Original